CompoAtlas

Capital Santé -Vitalité Globale

Food supplement declared in France, decision dated 22 July 2025

Capital Santé -Vitalité Globale (Forté Pharma) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: resvératrol 10 mg per day, ubiquinone 10 mg per day, Camellia sinensis 150 mg per day, Ginkgo biloba 120 mg per day, Zingiber officinale 30 mg per day. 3 rules of use apply to its ingredients (limits and warnings).

Brand
Forté Pharma
Food business operator placing the product on the market
Laboratoire FORTE PHARMA SA
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Powder
Daily dose
1 cuillère par jour
Directions for use
Prélever 1 cuillère doseuse remplie à ras bord et dissoudre dans un grand verre d'eau (200 ml ) ou shaker.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Femmes allaitantes, Autre : Vitalité- Soutien global de l'organisme, Femmes enceintes, Sous anticoagulants, Sous antidépresseurs, Sous antidiabétiques
Objectives stated by the manufacturer (these are not authorised claims)
Antioxydant, Articulations, Autre : Vitalité- Soutien global de l'organisme, Mémoire, Œil / Vision, Peau
Flavourings
Orange- Passion

Declaration 334798, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Camellia sinensis (L.) KuntzeFeuilleExtrait sec aqueux150 mg
Ginkgo biloba L.FeuilleExtrait sec hydroalcoolique120 mg
Zingiber officinale RoscoeRhizomeExtrait sec aqueux30 mg

Substances

NamePer day
resvératrol10 mg
ubiquinone10 mg

Other active ingredients

NamePer day
Collagène marinnot declared
Inulinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-pantothenate, calciumPantothenic acid (vitamin B5)no limit (insufficient data)dose annulled by the French Council of State in 2011
D-biotinBiotin (vitamin B8)no limit (insufficient data)dose annulled by the French Council of State in 2011
calcium salts of citric acidCalcium2,500 mg800 mg
Chlorure de chromeChromiumno limit (insufficient data)25 µg
cupric gluconateCopper5,000 µg2,000 µg
pteroylmonoglutamic acidFolate (vitamin B9)1,000 µg200 µg
potassium iodideIodine600 µg150 µg
magnesium salts of citric acidMagnesium250 mg300 mg
manganese gluconateManganese8 mg (safe level)3.5 mg
Molybdate de sodiumMolybdenum600 µg150 µg
nicotinamideNicotinamide (vitamin B3)900 mg54 mg
potassium salts of orthophosphoric acidPhosphorusno limit (insufficient data)450 mg
sodium selenateSelenium255 µg50 µg
retinyl acetateVitamin A3,000 µg d'équivalent rétinol800 µg
thiamin hydrochlorideVitamin B1 (thiamine)no limit (insufficient data)dose annulled by the French Council of State in 2011
cyanocobalaminVitamin B12no adverse effect defineddose annulled by the French Council of State in 2011
riboflavinVitamin B2 (riboflavin)no limit (insufficient data)dose annulled by the French Council of State in 2011
pyridoxine hydrochlorideVitamin B612 mg2 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg
cholecalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)
DL-alpha-tocopheryl acetateVitamin E300 mg30 mg
menaquinoneVitamin Kno limit (insufficient data)dose annulled by the French Council of State in 2011
zinc gluconateZinc25 mg15 mg

Additives

E950, E955, E160a, E330

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Contient de la caféine (9 mg maximum par dose journalière) et de l’EGCG (22,5 mg maximum par dose journalière), déconseillé aux femmes enceintes ou qui allaitent et aux enfants de moins de 18 ans. Déconseillé aux femmes enceintes ou désireuses de l’être, ainsi qu'aux femme ménopausées (vitamine A). Contient du thé vert, déconseillé en cas d’ulcère gastro-duodénal, de troubles cardiaques, ou d’hyperthyroïdie. Ne doit pas être consommé si vous prenez le même jour d’autres produits contenant du thé vert. Ne doit pas être consommé à jeun. Ne pas consommer 800 mg ou plus d’épigallocatéchine-3-gallate (EGCG) par jour. L’emploi chez les personnes sous antidiabétique et sous traitement antidépresseur est déconseillé. Déconseillé en cas d’obstruction biliaire ou d’autres troubles de la fonction biliaire. Réservé à l’adulte. Ne convient pas aux personnes traitées aux anticoagulants coumariniques (vitamine K). Déconseillé en cas d’épilepsie ou en cas d’acte interventionnel invasif programmé. Déconseillé en cas de prises de médicaments anticoagulants et antiagrégants plaquettaires. En cas de traitements médicamenteux, demander conseil à un professionnel de santé. Ne pas utiliser en cas de sensibilité à l’iode ou de troubles de la thyroïde (apporte au maximum 50 μg par dose journalière). Ce complément alimentaire n’est pas un médicament.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Ginkgo biloba L.
    Read the warning, when it applies and the studies cited

    GINKGO - GINKGO BILOBA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Sources cited by Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
    • OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    Sources cited by Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Contraindications

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    Sources cited by Health Canada (1)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    Sources cited by Health Canada (3)
    • Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematic review
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Health Canada monograph dated 25 July 2025

  • Zingiber officinale Roscoe
    Read the warning, when it applies and the studies cited

    GINGER - ZINGIBER OFFICINALE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 19 December 2025

  • ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Forté Pharma

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Capital Santé -Vitalité Globale (Forté Pharma): composition and regulation”, https://compoatlas.com/en/supplements/products/334798-capital-sante-vitalite-globale, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line